title: Patient's behavior and attitudes toward the management of benign prostatic hyperplasia among patients with the risk of disease progression: prospective study by "Prostate and Expectations of Treatment Epidemiology Research (PETER) study group".
abstract: BACKGROUND
  The aim of the study was to evaluate patients attitudes with benign prostatic hyperplasia at the risk of progression during a 12-month period of observation.
  
  
  METHODS
  A total of 426 patients from 45 outpatients centers were included and prospectively followed. Inclusion criteria were: age > 50 years, International Prostate Symptom Score (IPSS) > 8, prostate volume > 30 cm(3) (transabdominal ultrasound) and PSA > 1.5 to < 10 ng/ml.
  
  
  RESULTS
  In all, 28.6% patients were naive, 62.9% used monotherapy (alpha-blocker), and 8.5% combined treatment (alpha-blocker/5alpha-reductase inhibitor/dutasteride). The most bothersome symptoms were the weak urine stream (60.8%) and nocturia (59.2%). Patients expectations from the treatment were stabilization of the disease and reducing the risk of surgery rather than rapid resolution of symptoms. Despite the presence of symptoms, 2.3% patients claimed that benign prostatic hyperplasia/lower urinary tract symptoms had no impact on their quality of life (QoL), in 48.1 % only little impact on QoL, and 47.9% patients percepted their symptoms as severe. Out of 71.4% patients treated previously, 26.5% patients were indecisive about the satisfaction of present treatment. Visual analog score was percepted more optimistically rather than the IPSS. Pearson's correlation r = 0.68 at the beginning and r = 0.83 at the end of the study.
  
  
  CONCLUSIONS
  Prostate and Expectations of Treatment Epidemiology Research study highlights and reflects on patients behavior and self-perception, patients self-perception of the disease and therapeutic priorities during the 1 year of observation.
authors.affiliation: Department of Urology, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria, peter.weibl@meduniwien.ac.at.
authors.forename: Peter
authors.initials: P
authors.lastname: Weibl
authors.forename: Tobias
authors.initials: T
authors.lastname: Klatte
authors.forename: Peter
authors.initials: P
authors.lastname: Laurinc
authors.forename: Roman
authors.initials: R
authors.lastname: Tomaškin
authors.forename: Shahrokh F
authors.initials: SF
authors.lastname: Shariat
authors.forename: Miroslav
authors.initials: M
authors.lastname: Helbich
authors.forename: Danica
authors.initials: D
authors.lastname: Fackovcova
authors.forename: Peter
authors.initials: P
authors.lastname: Bujdák
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D015897:Comorbidity; D018450:Disease Progression; D004359:Drug Therapy, Combination; D000068538:Dutasteride / Q000627:therapeutic use; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000453:epidemiology / Q000473:pathology / Q000523:psychology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011446:Prospective Studies; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000453:epidemiology / Q000473:pathology / Q000523:psychology* / Q000628:therapy*; D012106:Research; D012306:Risk; D014463:Ultrasonography
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D017430:Prostate-Specific Antigen; D000068538:Dutasteride